The Biomarkers and Detection of Head and Neck Cancer, Volume II
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (29 February 2024)
Special Issue Editors
Interests: head and neck cancer; therapy resistance; immunotherapy; tumoroid; biomarkers
Special Issues, Collections and Topics in MDPI journals
Interests: HPV-related head and neck cancer; immunogenic cell death; immunotherapy; microenvironment
Special Issues, Collections and Topics in MDPI journals
Interests: head and neck cancer; patient care; innovative therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of "Biomarkers and Detection of Head and Neck Cancer" (https://www.mdpi.com/journal/cancers/special_issues/Biomarkers_Detection_Head_and_Neck_Cancer).
Head and neck squamous cell carcinomas (HNSCCs) represent the fifth most common cancer worldwide, with an annual incidence and mortality estimated to be approximately 600,000 and 375,000 cases, respectively. HNSCCs are related to alcohol and tobacco consumption and infection by high-risk Human Papillomaviruses (HPVs). Most patients present with advanced disease due to late diagnosis, and survival outcomes therefore remain poor, despite advances in therapeutic management and decades of research. In addition, conventional therapies including surgery and chemoradiation can leave survivors with significant morbidity and reduced quality of life. Immunotherapies have improved survival, but a durable response is observed in less than 20% of patients. Unlike other cancers, HNSCCs suffer from the absence of reliable diagnostic, prognostic, predictive, and theragnostic biomarkers. These markers are urgently needed in order to offer patients tailored therapeutic options that target specific molecular features of HNSCCs subgroups, to predict cancer cell resistance to treatment and detect the occurrence of relapse early.
In this Special Issue, we are inviting original research articles, reviews, and perspectives to present and discuss data on the biomarkers and detection of these tumors. Topics will include but are not limited to the biology and genomic characteristics of these cancers; the coding and noncoding transcriptome; the role of extracellular vesicles; biomarkers in tissue, blood, and biofluids; “liquid biopsies”; original tumor models such as tumoroids and tumoroids-on-chips; the identification of novel therapeutic targets or resistance mechanisms; and new approaches for treating these cancers. Work including multidisciplinary approaches (chemistry, physics, engineering, etc.) are welcome.
Dr. Sophie Martin
Dr. Alain C. Jung
Dr. Mickaël Burgy
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- liquid biopsies
- tumoroids
- targets
- therapy
